Gabapentin
Product Images NDC 63629-7309

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 63629-7309). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor for female patients. The formula includes the expression: CLCr = [140 - age (years)] x weight (kg) / 72 x serum creatinine (mg/dL), multiplied by 0.85 for female patients.*

FDA Label Image

1 (Image 2)

Gabapentin by Bryant Ranch Prepack, shown as a white oval tablet. The tablet is imprinted with 'GNP' on one side and the number '600' on the other, indicating a 600 mg strength.*

FDA Label Image

1 (Image 3)

Gabapentin oral capsules in a clear plastic strip with a white backing. The image shows a partial view of the blister pack containing round, brown capsules. No additional label or text is visible to specify strength or quantity. Labeler is Bryant Ranch Prepack.*

FDA Label Image

1 (Image 4)

Gabapentin capsules packaging displaying the brand name Gabapentin on a white label with blue and orange accents. The label includes the strength and dosage form as capsules, with branding from Bryant Ranch Prepack. The image shows the label wrapped around a white plastic bottle with an orange child-resistant cap.*

FDA Label Image

1 (Image 5)

Chemical structure of Gabapentin, showing a cyclohexane ring bonded to amino (CH2NH2) and carboxymethyl (CH2CO2H) groups.*

FDA Label Image

1 (Image 6)

A line graph showing mean pain score over 8 weeks for two groups: placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score, with Gabapentin showing a marked reduction compared to placebo.*

FDA Label Image

2 (Image 7)

A line graph showing mean pain scores over a 7-week period for three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period, tracking changes from baseline to week 7.*

FDA Label Image

3 (Image 8)

A bar graph comparing percentage outcomes for placebo (PBO) and different doses of Gabapentin (GBP) in two separate studies. Study 1 shows 12% for PBO and 29% for GBP 3600. Study 2 shows 14% for PBO, 32% for GBP 1800, and 34% for GBP 2400, with significance levels indicated by asterisks above the bars.*

FDA Label Image

4 (Image 9)

A scatter plot showing differences (%) on the vertical axis and daily dose (mg) on the horizontal axis with three sets of data points labeled Study a, Study b, and Study c. Each study is represented by different symbols and plotted at daily doses of approximately 600, 900, 1200, and 1800 mg.*

FDA Label Image

Label Image (Lbl636297309)

Gabapentin 400mg (CV) capsule packaging label by Bryant Ranch Prepack, Burbank, CA. The label compares to Neurontin 400mg capsules by Watson Pharma Private Limited, with a package count of 90. Capsule color is indicated as orange/light brown with a logo '667'. Storage instructions specify room temperature 20°-25°C (68°-77°F). Includes standard warnings and a barcode with NDC 63629-7309-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.